Plasma Therapy and Transfusion Technology最新文献

{"title":"Current status of bone marrow purging prior to autografting for Hematological malignancies—future directions","authors":"P. Hervé","doi":"10.1016/0278-6222(88)90042-3","DOIUrl":"10.1016/0278-6222(88)90042-3","url":null,"abstract":"<div><p>While the debate remains largely open concerning the importance of purging in malignant hemopathies, we are currently witness to the extraordinary development of complex and expensive technologies associating several methods (immunochemoseparation procedure, drug cocktails …). Such techniques may be justified for acute leukemias at high risk of relapse when the residual disease is almost perceptible. Current objectives are oriented in several directions: development of techniques for detecting residual disease, development of immunophysical procedure (magnetic and floating immunobeads) and long-term human marrow cultures for selection of normal hematopoietic stem cells. Future progress in ABMT depends not only on the effective <em>ex-vivo</em> purging of marrow but also on development of more effective conditioning regimens (<em>in vivo</em> purging).</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 1","pages":"Pages 103-113"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90042-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80453054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of apheresis on iron stores","authors":"Vanessa J. Martlew MB, MRCP, MRCPath ,&nbsp;H.M. Waters MSc, FIMLS ,&nbsp;J.E. Howarth BSc, FIMLS, DMLM","doi":"10.1016/0278-6222(88)90012-5","DOIUrl":"10.1016/0278-6222(88)90012-5","url":null,"abstract":"<div><p>Monthly plasmapheresis of volunteer donors was introduced at the Manchester Apheresis Centre late in 1985. Serum ferritin was measured at the outset and after 12 months regular donation to monitor iron stores. In a cohort of 100 male and 86 female blood donors it was found that both groups had mean serum ferritins lower than non-donor controls. A year after conversion to monthly plasma donation the female donors were found to increase mean serum ferritin almost to that of the control subjects while a much smaller rise was observed in their male counterparts.</p><p>It was concluded that plasmapheresis is conservative of iron stores, and the benefits are apparent earlier in females.</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 4","pages":"Pages 343-346"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90012-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76478486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation and transfusion of neocytes: Experience in children with thalassemia","authors":"Giancarlo Isacchi MD,&nbsp;Nicola Giuliano,&nbsp;Lucia Granati MD,&nbsp;Giuseppe Polino MD,&nbsp;Pellegrina Pugliese MD,&nbsp;Vittorio Rosato PhD,&nbsp;Francesco Malagnino MD","doi":"10.1016/0278-6222(88)90024-1","DOIUrl":"10.1016/0278-6222(88)90024-1","url":null,"abstract":"<div><p>The use of neocytes has been developed as a system to reduce transfusion requirement and consequent iron overload. Neocyte concentrates prepared with the IBM 2991 Blood Processor have been transfused in 14 patients with Cooley's anemia (two groups of nine and five patients respectively). Analysis of the clinical advantages of neocytes has demonstrated that (1) the reduction of the blood requirement was about 10%; (2) the cost of a neocyte unit is considerable compared with the standard blood unit; and (3) the risk of alloimmunization and blood-dependent infectious disease is increased, in proportion to the large numbers of blood donors.</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 1","pages":"Pages 7-10"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90024-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82165238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulation of T and B cell subpopulations during high dose intravenous immunoglobulin therapy","authors":"M.G. Macey MSc,&nbsp;A.C. Newland MRCP, MRCPath","doi":"10.1016/0278-6222(88)90046-0","DOIUrl":"10.1016/0278-6222(88)90046-0","url":null,"abstract":"<div><p>The absolute number of T and B lymphocytes in 15 patients before, during and after high dose intravenous infusions of immunoglobulin (IgG) solution was determined. 12 patients (10 chronic, 2 acute) had idiopathic thrombocytopenic purpura (ITP), one had auto immune haemolytic anaemia (AIHA), one had Evans Syndrome and another had acquired haemophilia with antibodies to Factor VIII. In 14 of the patients, a reduction in total lymphocyte count was observed during the infusion period; this correlated with a reduction in B cell numbers. The total number of T lymphocytes was constant but a reduction in the helper/inducer (T4) subset and an increase in the suppressor/cytotoxic (T8) subset occurred. A corresponding reduction in purified protein derivative (PPD) and pokeweed mitogen (PWM) transformation indices was detected. These findings occurred in 13 of the patients in association with a positive clinical response and we speculate that, in many patients receiving intravenous IgG, an alteration in the immune response occurs, and that, in conjunction with other mechanisms, this probably affects the patient's clinical state.</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 1","pages":"Pages 139-147"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90046-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80860509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modelling of LDL-apheresis: System efficacy and rebound kinetics","authors":"Frank Kochinke,&nbsp;Hans von Baeyer,&nbsp;Ingo Schwaner,&nbsp;Hartmut Gräfenhahn,&nbsp;Axel Nold,&nbsp;Rainer Schwerdtfeger,&nbsp;Wolfgang Schwartzkopff","doi":"10.1016/0278-6222(88)90030-7","DOIUrl":"10.1016/0278-6222(88)90030-7","url":null,"abstract":"","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 1","pages":"Pages 35-44"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90030-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77953707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How fit are blood donors?","authors":"Vanessa J. Martlew MB, MRCP, MRCPath,&nbsp;Gillian M. Cockersole MBChB","doi":"10.1016/0278-6222(88)90010-1","DOIUrl":"10.1016/0278-6222(88)90010-1","url":null,"abstract":"<div><p>Recruited from the panel of whole blood donors, volunteers under the age of 40 yr were submitted to medical examination before embarking on regular plasmapheresis. Of the first 1000 (9.4%), were found unfit and of these, the majority (8.6%) were also unsuited to whole blood donation according to the selection criteria of the Transfusion Service of the United Kingdom. In the absence of frequent untoward events at blood collection sessions, our findings beg the question—how fit are blood donors and/ or how fit do they need to be?</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 4","pages":"Pages 333-336"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90010-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83965153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell apheresis in patients with acute nonlymphocytic leukemia","authors":"J. Reiffers ,&nbsp;G. Vezon ,&nbsp;Ph. Bernard ,&nbsp;A. Sarrat ,&nbsp;J. Chevaleyre ,&nbsp;G. Marit ,&nbsp;B. David ,&nbsp;R. Bouzgarrou ,&nbsp;A. Broustet","doi":"10.1016/0278-6222(88)90043-5","DOIUrl":"10.1016/0278-6222(88)90043-5","url":null,"abstract":"<div><p>In patients with acute nonlymphocytic leukemia (ANLL) it has previously been reported that the number of blood-derived hemopoietic stem cells (HSC) is very low during the remission phase.^1,2 However, we and others have recently demonstrated that the concentration of granulocyte-macrophage precursors (CFU-GM cells) in the peripheral blood could be increased to 10- to 40-fold above the mean value in normal subjects during the period of marrow reconstitution following aplasia (or hypoplasia) induced by previous chemotherapy.^1,3 To collect high numbers of circulating HSC, leukocyta-phereses could be performed during this short period of “recirculation” of blood-derived progenitors.</p><p>However, patients with ANLL may be subjected to different chemotherapy regimens that vary according to the age of the patients, the status of the leukemia, and the therapeutic strategy. The amplitude of the recirculation of CFU-GM cells during remission is influenced mostly by the type of chemotherapy administered to the patient.¹ In order to evaluate this phenomenon, we serially assayed peripheral blood CFU-CM cells in 26 ANLL patients. The mean value of the highest recorded peak (HRP) level was 4370 CFU-GM/mL (1133 to 9066) in 13 patients who achieved complete remission after a single course of induction treatment including cytosine arabinoside (Ara-c) (100 mg/m2 × 10 days) and daunorubicin (DNR) (60 mg/m2 × 3 days). As mentioned in a previous report, HPR levels of CFU-GM cells observed in two patients given a late, intensification treatment (with DNR: 300 mg/m2) were similar to those observed in these latter 13 patients.¹ The recirculation of CFU-GM cells was less marked in seven patients who received two consecutive courses of induction chemotherapy or in four other patients receiving less intensive treatment as consolidation.^1,2 These results confirm the results of our previous report and the data reported by To et al., who studied 13 ANLL patients during the very early remission phase following induction chemotherapy.³ They found that the mean value of the HRP level of CFU-GM cells was 2796/mL (370 to 14520) and concluded that the early remission period after one single course of chemotherapy could be the best time for collection of circulating HSC in ANLL patients.</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 1","pages":"Pages 115-118"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90043-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85337921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigations on lipid storage disease under apheresis therapy","authors":"U. Wellner","doi":"10.1016/0278-6222(88)90027-7","DOIUrl":"10.1016/0278-6222(88)90027-7","url":null,"abstract":"","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 1","pages":"Pages 25-26"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90027-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85216321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low density lipoprotein — apheresis with dextran sulfate-cellulose: Development of a selective chemical adsorption system of plasma components","authors":"Shinji Yokoyama","doi":"10.1016/0278-6222(88)90028-9","DOIUrl":"10.1016/0278-6222(88)90028-9","url":null,"abstract":"","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 1","pages":"Pages 27-28"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90028-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80587693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High dose intravenous immunoglobulin in post transfusion purpura—Changes in bound and free platelet antibody and in vitro lymphocyte transformation with Phytohemagglutinin","authors":"A. Oral,&nbsp;F. Solano,&nbsp;A. Crimaldi,&nbsp;D. Salamon,&nbsp;M.V. Griffin","doi":"10.1016/0278-6222(88)90016-2","DOIUrl":"10.1016/0278-6222(88)90016-2","url":null,"abstract":"<div><p>A middle-aged female with posttransfusion purpura (PTP), serologically proven to be associated with anti-PLAI antibody was treated successfully with high-dose intravenous immunoglobulin (IVIG). Normalization of the Platelet Associated IgG-antibody (PAIgG) correlated with peak platelet count on day 6 of therapy. Anti-PLAI antibody was detectable until week 5 of the follow-up period. Impaired pre-therapy lymphocyte transformation with Phytohemagglutinin (PHA) corrected with the disappearance of the Anti-PLAI antibody.</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"9 4","pages":"Pages 359-363"},"PeriodicalIF":0.0,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0278-6222(88)90016-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89636031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}